Dr. Megan E. Buechel
Claim this profileAscension Saint Vincent Indianapolis Hospital
Area of expertise
Uterine Cancer
Megan E. Buechel has run 4 trials for Uterine Cancer. Some of their research focus areas include:
Endometrial Adenocarcinoma
Megan E. Buechel has run 3 trials for Endometrial Adenocarcinoma. Some of their research focus areas include:
Affiliated Hospitals
Ascension Saint Vincent Indianapolis Hospital
Clinical Trials Megan E. Buechel is currently running
Tailored Therapy
for Endometrial Cancer
This phase II trial tests how well tailoring therapy in post-surgery works in patients with low-risk endometrial cancer. The usual approach for patients with low-risk endometrial cancer is treatment with surgery. In this study, tissue that is removed as part of the surgical procedure is analyzed in the pathology laboratory to help guide the doctor to decide whether or not additional treatment such as radiation and or chemotherapy should be recommended.
Recruiting
1 award
Phase 2
4 criteria
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting
2 awards
Phase 3
More about Megan E. Buechel
Clinical Trial Related
1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Megan E. Buechel has experience with
- Brachytherapy
- External Beam Radiation Therapy
- Pembrolizumab
- Carboplatin
- Paclitaxel
- Pertuzumab
Breakdown of trials Megan E. Buechel has run
Uterine Cancer
Endometrial Adenocarcinoma
Fallopian Tube Carcinosarcoma
Endometrial Cancer
Uterine Carcinosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Megan E. Buechel specialize in?
Megan E. Buechel focuses on Uterine Cancer and Endometrial Adenocarcinoma. In particular, much of their work with Uterine Cancer has involved Stage I patients, or patients who are Stage III.
Is Megan E. Buechel currently recruiting for clinical trials?
Yes, Megan E. Buechel is currently recruiting for 2 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Megan E. Buechel has studied deeply?
Yes, Megan E. Buechel has studied treatments such as Brachytherapy, External Beam Radiation Therapy, Pembrolizumab.
What is the best way to schedule an appointment with Megan E. Buechel?
Apply for one of the trials that Megan E. Buechel is conducting.
What is the office address of Megan E. Buechel?
The office of Megan E. Buechel is located at: Ascension Saint Vincent Indianapolis Hospital, Indianapolis, Indiana 46260 United States. This is the address for their practice at the Ascension Saint Vincent Indianapolis Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.